C4 Therapeutics, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $35.9M | $35.6M | $20.8M | $31.1M | $45.8M |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Gross Margin | — | — | — | — | — |
| Operating Expenses | |||||
| Research & Development | $104.2M | $110.6M | $117.7M | $117.8M | $94.7M |
| SG&A Expense | $36.2M | $42.1M | $42.1M | $42.8M | $33.3M |
| Operating Income | $-115.2M | $-119.6M | $-139.0M | $-129.5M | $-82.1M |
| Operating Margin | -320.5% | -336.1% | -669.8% | -416.6% | -179.4% |
| Interest Expense | — | — | — | — | — |
| Pretax Income | $-104.9M | $-105.2M | $-131.2M | $-128.2M | $-83.9M |
| Income Tax Expense | $121.0K | $131.0K | $1.3M | $0 | $0 |
| Net Income | $-105.0M | $-105.3M | $-132.5M | $-128.2M | $-83.9M |
| Net Margin | -292.1% | -296.0% | -638.3% | -412.2% | -183.2% |
| EPS (Basic) | $-1.27 | $-1.52 | $-2.67 | $-2.62 | $-1.82 |
| EPS (Diluted) | $-1.27 | $-1.52 | $-2.67 | $-2.62 | $-1.82 |
| Shares Outstanding (Basic) | 82.9M | 69.4M | 49.6M | 48.9M | 46.0M |
| Shares Outstanding (Diluted) | 82.9M | 69.4M | 49.6M | 48.9M | 46.0M |
| Dividends Per Share | — | — | — | — | — |